Pyxis Oncology Inc (PYXS) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $21.4M

PYXS ranks #5100 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

PYXS is a top-conviction position for GordonMD Global Investments LP — at 14.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

PYXS is down 1% today, but institutions show net buying of $21.4M this quarter — a divergence between today's price move and the underlying institutional flow.

PYXS reported a net loss of $88.7M over the trailing twelve months.

• Not yet profitable — net loss of $88.7M over the trailing twelve months
• Revenue declined 14.2% year over year
• Net income improved year over year, from -$96.3M to -$88.7M
• Operating cash flow was negative, using $63.5M in cash
• Current ratio of 3.41x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.71x equity — within a conventional range